(1S)-1-(5,6-dichloro-1H-benzimidazol-2-yl)ethanamine | 1360599-73-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (1S)-1-(5,6-dichloro-1H-benzimidazol-2-yl)ethanamine
• CAS: 1360599-73-0
• 化学式: C₉H₉Cl₂N₃
• 分子量: 230.097
• InChiKey: ZCWJKEZMWZLCBF-BYPYZUCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1S)-1-(5,6-dichloro-1H-benzimidazol-2-yl)ethanamine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 (2S,3S)-2-amino-N-[(1S)-1-(5,6-dichloro-1H-benzimidazol-2-yl)ethyl]-3-(4-phenylphenyl)butanamide
  参考文献：
  名称：

  Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine

  摘要：

  Efforts to modify the central proline portion of lead compound 4 lead to the discovery of novel prolylcarboxypeptidase (PrCP) inhibitors. Especially, replacement with alanine afforded compound 19 displaying more potent human and mouse PrCP inhibitory activity than 4 and an overall comparable profile. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.12.064
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以100%的产率得到(1S)-1-(5,6-dichloro-1H-benzimidazol-2-yl)ethanamine
  参考文献：
  名称：

  Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine

  摘要：

  Efforts to modify the central proline portion of lead compound 4 lead to the discovery of novel prolylcarboxypeptidase (PrCP) inhibitors. Especially, replacement with alanine afforded compound 19 displaying more potent human and mouse PrCP inhibitory activity than 4 and an overall comparable profile. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.12.064

文献信息

• Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine
  作者：Zhicai Wu、Cangming Yang、Yusheng Xiong、Zhe Feng、Matthew Lombardo、Andreas Verras、Renee M. Chabin、Suoyu Xu、Xinchun Tong、Dan Xie、Mike E. Lassman、Urmi R. Bhatt、Margarita M. Garcia-Calvo、Wayne Geissler、Zhu Shen、Qing Chen、Ranabir Sinharoy、Jeffrey J. Hale、James R. Tata、Shirly Pinto、Dong-Ming Shen、Steven L. Colletti

  DOI：10.1016/j.bmcl.2011.12.064

  日期：2012.2

  Efforts to modify the central proline portion of lead compound 4 lead to the discovery of novel prolylcarboxypeptidase (PrCP) inhibitors. Especially, replacement with alanine afforded compound 19 displaying more potent human and mouse PrCP inhibitory activity than 4 and an overall comparable profile. (C) 2011 Published by Elsevier Ltd.